Search
Protara Therapeutics Inc
TARAAdd to Watchlist
3.350USD
-0.190-5.37%
Close 09-24 16:00（ET）
188.27MMarket Cap
LossP/E TTM
Protara Therapeutics Inc (TARA) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts giving stock ratings to Protara Therapeutics Inc in the past month.
Buy
1 Strong Buy
7 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
25.667USD+625.05%
TARA Analyst Recommendation Trends
In the current month, TARA has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TARA average Analyst price target in the last month is 25.667.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
1
1
1
1
1
1
1
1
7
7
7
7
7
7
6
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
8
8
8
8
8
7
7
TARA Analyst Rating for Peer Comparison
Updated: Sep 24, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, TARA EPS is projected to reach -0.366 in FY2026Q3, following reported EPS of -0.355 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.33
-0.37
-0.33
-0.37
-0.37
Actual
-0.38
-0.31
-0.36
--
--
Surprise
-15.58%
+17.43%
-9.04%
--
--
FAQs
What is Protara Therapeutics Inc's price target?
Analysts forecast that Protara Therapeutics Inc's price target is USD 25.67, with the highest forecast at USD 30.00 and the lowest forecast at USD 20.00.
How have Protara Therapeutics IncTARA's recent earnings per share performed?
The market expectation was USD -0.36, while Protara Therapeutics IncTARA's earnings per share (EPS) for the previous quarter was USD -0.31. EPS for the next quarter is expected at USD -0.37.
What is the analyst rating for Protara Therapeutics Inc?
Based on the ratings of Protara Therapeutics Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.